Carvykti's success boosts Legend Biotech Corporation's Q4 2024 sales to $334M, solidifying market position. Click to find out ...

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...

Legend Biotech Corp (LEGN) reports a 110% increase in CARVYKTI sales, outlines expansion strategies, and anticipates ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Q4 2024 Earnings Call Transcript March 11, 2025 Legend Biotech Corporation beats earnings expectations. Reported EPS is $0.08 ...

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 ...

Legend Biotech’s (LEGN) shares have surged over 10% in the past few days, spurred by the company’s latest earnings report, thanks to ...

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of CA ...